-

Shareholder Alert: Robbins LLP Reminds Investors Groupon, Inc. (GRPN) Sued for Misleading Shareholders

SAN DIEGO & CHICAGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Groupon, Inc. (NASDAQ: GRPN) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between November 4, 2019 and February 18, 2020. Groupon operates online local commerce marketplaces that connect merchants to consumers by offering goods and services at a discount.

If you suffered a loss as a result of Groupon's misconduct, click here.

Groupon, Inc. (GRPN) Accused of Misleading Shareholders

According to the complaint, on November 4, 2019, Groupon announced its third quarter 2019 financial results stating, "We believe that the improvements we're making to the customer experience…will encourage our customers to return to Groupon again and again" and that the Company was looking forward to its sales in the holiday season. Groupon then announced an expected adjusted EBITDA of approximately $270 million for full year 2019. Despite its positive forward-looking statements, on February 18, 2020, Groupon reported a 23% decline in sales year-over-year, and an adjusted EBITDA for 2019 of $227.2 million, a significant miss from its previous $270 million forecast. When asked about the disappointing results, Groupon cited lower customer engagement in its Goods category, which lowered overall traffic and "ultimately impeded performance in all of our categories" with a notable adverse impact to its holiday peak period. On this news, Groupon's share price fell over 44% to close at $1.70 per share. A little over a month after the announcement, both its CEO and COO were removed from their positions.

Groupon, Inc. (GRPN) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:GRPN

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom